The Effect of Tetrathiomolybdate on Cytokine Expression, Angiogenesis, and Tumor Growth in Squamous Cell Carcinoma of the Head and Neck | Head and Neck Cancer | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.186.91. Please contact the publisher to request reinstatement.
JAMA Network Home
JAMA Otolaryngology–Head & Neck Surgery
full text icon
Full Text
 contents icon
Contents
 figure icon
Figures /
Tables
 multimedia icon
Multimedia
 attach icon
Supplemental
Content
 references icon
References
 related icon
Related
 comments icon
Comments
1.
Mann  ESpiro  JChen  LKreutzer  D Cytokine expression by head and neck squamous cell carcinoma.  Am J Surg 1992;164567- 573PubMedGoogle ScholarCrossref
2.
Cohen  RContrino  JSpiro  JMann  EChen  LKreutzer  D Interleukin-8 expression by head and neck squamous cell carcinoma.  Arch Otolaryngol Head Neck Surg 1995;121202- 209PubMedGoogle ScholarCrossref
3.
Woodworth  CMcMullin  EIglesias  MPlowman  G Interleukin 1α and tumor necrosis factor α stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells.  Proc Natl Acad Sci U S A 1995;922840- 2844PubMedGoogle ScholarCrossref
4.
Smith  DPolverini  PKunkel  S  et al.  Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma.  J Exp Med 1994;1791409- 1415PubMedGoogle ScholarCrossref
5.
Chen  ZColon  IOrtiz  N  et al.  Effects of interleukin-1α, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines.  Cancer Res 1998;583668- 3676PubMedGoogle Scholar
6.
Chen  ZMalhotra  PSThomas  GR  et al.  Expression of proinflammatory and proangiogenic cytokines in human head and neck cancer patients.  Clin Cancer Res 1999;51369- 1379PubMedGoogle Scholar
7.
Van Waes  CChen  ZCallister  M  et al Cytokines in the immune pathogenesis and therapy of head and neck cancer.  In: Veldman  JE, Passali  D,Lim  DJ, eds. Immuno- and Molecular Biology in ORL—State of Art. The Hague, the Netherlands: Kubler Publications. In press Google Scholar
8.
Ondrey  FGDong  GSun Woo  J  et al.  Constitutive activation of transcription factor NFκB, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express proinflammatory and proangiogenic cytokines.  Mol Carcinog 1999;26119- 129PubMedGoogle ScholarCrossref
9.
Young  MRWright  MALozano  Y  et al.  Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte macrophage colony stimulating factor and contains CD34 plus natural suppressor cells.  Int J Cancer 1997;7469- 74PubMedGoogle ScholarCrossref
10.
Beg  AABaltimore  D An essential role for NFκB in preventing TNFα induced cell death.  Science 1996;274782- 784PubMedGoogle ScholarCrossref
11.
Duffey  DCChen  ZDong  G  et al.  Expression of dominant negative mutant inhibitor-κB of nuclear factor κB in human head and neck squamous cell carcinoma inhibits survival proinflammatory cytokine expression in vivo.  Cancer Res 1999;593468- 3474PubMedGoogle Scholar
12.
Sunwoo  JBChen  ZDong  G  et al.  Novel Proteosome inhibitor PS-341 inhibits activation of nuclear factor κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.  Clin Cancer Res 2001;71419- 1428PubMedGoogle Scholar
13.
Cox  CTeknos  TNBarrios  MBrewer  GJDick  RDMerajver  SD The role of copper suppression as an antiangiogeneic strategy in head and neck squamous cell carcinoma.  Laryngoscope 2001;111696- 701PubMedGoogle ScholarCrossref
14.
Pan  QKleer  CGVan Golen  KL  et al.  Copper deficiency induce by tetrathiomolybdate suppresses tumor growth and angiogenesis.  Cancer Res 2002;624854- 4859PubMedGoogle Scholar
15.
Landriscina  MBagala  CMandanova  A  et al.  Copper induces the assembly of a multiprotein aggregate implicated in the release of fibroblast growth factor 1 in response to stress.  J Biol Chem 2001;27625549- 25557PubMedGoogle ScholarCrossref
16.
Krause  CCarey  TEOtt  RHurbis  CMcClatchey  KRegezi  J Human squamous cell carcinoma establishment in characterization of new permanent cell lines.  Arch Otolaryngol 1981;107703- 710PubMedGoogle ScholarCrossref
17.
White  ESStrom  SRBWys  NLArenberg  DA Non small cell lung cancer cells induce monocytes to increase expression of angiogenetic activity.  J Immunol 2001;1667549- 7555PubMedGoogle ScholarCrossref
18.
Nor  JEPeters  MCChristensen  JB  et al.  Engineering and characterization of functional human vessels in immunodeficient mice.  Lab Invest 2001;81453- 463PubMedGoogle ScholarCrossref
19.
Mandinov  LMandinova  AKyurkchiev  S  et al.  Copper chelation represses the vascular response to injury.  Proc Natl Acad Sci U S A 2003;1006700- 6705PubMedGoogle ScholarCrossref
20.
Brewer  GJDick  RDYuzbasiyan-Gurkin  VTankanow  RYoung  ABKluin  KG Initial therapy of patients with Wilson’s disease with tetrathiomolybdate.  Arch Neurol 1991;4842- 47PubMedGoogle ScholarCrossref
21.
Hu  GF Copper stimulates proliferation of human endothelial cells under culture.  J Cell Biochem 1998;69326- 335PubMedGoogle ScholarCrossref
22.
McAuslan  BRReilly  W Endothelial cell phagokinesis in response to specific metal ions.  Exp Cell Res 1980;130147- 157PubMedGoogle ScholarCrossref
23.
Brewer  GJDick  RDGrover  DK  et al.  Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent; phase I study.  Clin Cancer Res 2000;61- 10PubMedGoogle Scholar
24.
Redman  BGEsper  PPan  Q  et al.  Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.  Clin Cancer Res 2003;91666- 1672PubMedGoogle Scholar
25.
Mandinova  ASoldi  RGranziani  I  et al.  S100A13 mediates the copper-dependent stress-induced release of IL-1α from both human U937 and murine NIH 3T3 cells.  J Cell Sci 2003;1162687- 2696PubMedGoogle ScholarCrossref
26.
Landriscina  MBagala  CMandinova  A  et al.  Copper induces the assembly of a multiprotein aggregate implicated in the release of fibroblast growth factor 1 in response to stress.  J Biol Chem 2001;27625549- 25557PubMedGoogle ScholarCrossref
27.
Hemker  HCVan Rijn  JLRosing  JVan Dieijen  GBevers  EMZwaal  RF Platelet membrane involvement in blood coagulation.  Blood Cells 1983;9303- 317PubMedGoogle Scholar
28.
Galang  CKGarcia-Ramirez  JSolski  PA  et al.  Oncogenetic Neu/ErbB-2 increases ets, AP-1, and NF-κB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation.  J Biol Chem 1996;2717992- 7998PubMedGoogle ScholarCrossref
29.
Teknos  TNCox  CChepeha  DBBradford  CRFisher  SWolf  GT Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma.  Laryngoscope 2002;112844- 851PubMedGoogle ScholarCrossref
30.
Teknos  TNCox  CYoo  S  et al.  Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma.  Head Neck 2002;241004- 1011PubMedGoogle ScholarCrossref
31.
Wang  CYCusack  JC  JrLiu  RBaldwin  AS  Jr Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB.  Nat Med 1999;5412- 417PubMedGoogle ScholarCrossref
32.
Wang  CYMayo  MWBaldwin  AS  Jr TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB.  Science 1996;274784- 787PubMedGoogle ScholarCrossref
33.
Cox  CMerajver  SDYoo  S  et al.  Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model.  Arch Otolaryngol Head Neck Surg 2003;129781- 785PubMedGoogle ScholarCrossref
This Issue
Citations 31
View Metrics
Original Article
March 2005

The Effect of Tetrathiomolybdate on Cytokine Expression, Angiogenesis, and Tumor Growth in Squamous Cell Carcinoma of the Head and Neck

Theodoros N. Teknos, MD; Mozaffarul Islam, PhD; Douglas A. Arenberg, MD; et al Quintin Pan, PhD; Shannon L. Carskadon, BS; Aaron M. Abarbanell, BS; Benjamin Marcus, MD; Supriti Paul, MD; Curtis D. Vandenberg, MD; Michael Carron, MD; Jacques E. Nor, DDS, PhD; Sofia D. Merajver, MD, PhD
Article Information
Arch Otolaryngol Head Neck Surg. 2005;131(3):204-211. doi:10.1001/archotol.131.3.204
visual abstract icon
Visual
Abstract
 editorial comment icon
Editorial
Comment
 related articles icon
Related
Articles
 author interview icon
Interviews
 multimedia icon
Multimedia
Abstract

Objective  To assess the effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth rate in human squamous cell carcinoma (SCC).

Design  Three human SCC cell lines were used in this study for both in vitro and in vivo investigations. Conditioned media from untreated and tetrathiomolybdate-treated cell lines were compared with regard to cytokine levels, endothelial cell chemotaxis, endothelial cell tubule formation, and migration and the ability to induce angiogenesis in a rat aortic ring array. In vivo UM-SCC-38 was seeded onto tissue-engineered scaffolds and surgically implanted into the flanks of immunodeficient mice. Tumor growth rates and the level of angiogenesis were compared after 2 weeks of therapy.

Setting  A tertiary care facility.

Results  In this study, we demonstrate that tetrathiomolybdate significantly decreases the secretion of interleukin 6 and basic fibroblast growth factor by head and neck SCC (HNSCC) cell lines in vitro. Furthermore, we demonstrate that tetrathiomolybdate significantly decreases the secretion of interleukin 6 and basic fibroblast growth factor by HNSCC cell lines in vitro. Furthermore, tetrathiomolybdate treatment of HNSCC cell lines results in significantly decreased endothelial cell chemotaxis, tubule formation, and neovascularization in a rat aortic ring assay. This in vitro evidence of decreased angiogenesis by tetrathiomolybdate is confirmed in vivo by using a severe combined immunodeficiency disorder mouse model in which tetrathiomolybdate therapy is shown to prevent human blood vessel formation. Finally, human HNSCC implanted into immunodeficient mice grow to a much larger size in untreated mice compared with those treated with 0.7 mL/kg per day of oral tetrathiomolybdate.

Conclusions  These findings illustrate the ability of tetrathiomolybdate to down-regulate proinflammatory and proangiogenic cytokines in HNSCC. These observations are potentially exciting from a clinical perspective because a global decrease in these cytokines may decrease tumor aggressiveness and reverse the resistance to chemotherapy and radiation therapy seen in this tumor type.

×